Vistagen cuts workforce 20%, cites cash management; PALISADE-4 results expected H1 2026

Vistagen Therapeutics, Inc.

Reduced workforce by approximately 20% to prioritize fasedienol PALISADE-4 Phase 3 trial.
Topline results from PALISADE-4 for social anxiety disorder expected first half of 2026.
Company expects cash runway to extend into 2027 after the workforce reduction.
Affected employees may receive cash severance and healthcare coverage; costs expected immaterial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.